PAVmed (PAVM) Stock Price, News & Analysis

Company Overview

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.99 to $1.10
• 50-Day Range: $1.00 to $1.78
• 52-Week Range: $0.60 to $4.88
• Volume: 43,175 shs
• Average Volume: 51,525 shs
• Market Capitalization: $11.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Strong Buy

PAVmed Stock Analysis - MarketRank™

PAVmed scored higher than 80% of companies evaluated by MarketBeat, and ranked 229th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

PAVmed has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PAVmed has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PAVmed are expected to grow in the coming year, from ($5.17) to ($4.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PAVmed is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PAVmed is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.25% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in PAVmed has recently increased by 1.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PAVmed does not currently pay a dividend.

Dividend Growth

PAVmed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

3.25% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in PAVmed has recently increased by 1.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

PAVmed has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for PAVmed this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for PAVM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added PAVmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PAVmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.70% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.93% of the stock of PAVmed is held by institutions.

PAVM Stock Analysis - Frequently Asked Questions

How have PAVM shares performed this year?

PAVmed's stock was trading at $4.12 at the beginning of 2024. Since then, PAVM stock has decreased by 75.0% and is now trading at $1.03.
View the best growth stocks for 2024 here.

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) posted its quarterly earnings results on Thursday, August, 12th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.50) by $0.60.

When did PAVmed's stock split?

PAVmed shares reverse split before market open on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of PAVmed?

Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of PAVmed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Palantir Technologies (PLTR) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/12/2021
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PAVM
• CUSIP: N/A
• CIK: 1624326
• Web: www.pavmed.com
• Phone: (212) 949-4319
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +1,938.8%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-64,180,000.00
• Net Margins: 602.97%
• Pretax Margin: 244.87%
• Return on Equity: N/A
• Return on Assets: -92.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $2.45 million
• Price / Sales: 4.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.35) per share
• Price / Book: -0.31

Miscellaneous

• Outstanding Shares: 11,070,000
• Free Float: 9,442,000
• Market Cap: $11.40 million
• Optionable: Optionable
• Beta: 0.69